Why Summit Therapeutics Inc. (SMMT) Stock Fell 13.4% on Sep 29, 2026
The clearest new catalyst: Form 8-K filing.
Why did SMMT stock fall?
Summit Therapeutics fell 13.4% on September 29, 2026, closing at $16.35. A Form 8-K filing was submitted on that date, though the specific disclosure triggering the decline is not detailed in available sources. Stifel reiterated a Buy rating with a $38 price target, suggesting analyst confidence despite the session's weakness.
- Form 8-K filing: Summit Therapeutics filed a Form 8-K on September 29, 2026, the same date as the sharp decline, though the specific material event disclosed in the filing is not specified in available sources.
- Analyst support amid weakness: Stifel reiterated a Buy rating on SMMT with a $38 price target, indicating analyst conviction in upside potential despite the stock's recent 10% decline over the prior week.
Initial detection
BestStocks first flagged SMMT intraday on Sep 29, 2026; this analysis was finalized after the close using the confirmed −13.4% session move and additional catalyst research.
Show the initial intraday note
SMMT moved -13.35% from its $18.87 open to a $16.35 close on 2026-09-29.
What to watch next: Monitor next session.
Other developments that session
Summit Therapeutics Inc. moved +4.94% intraday from $15.48 to $16.25. Summit Therapeutics SMMT stock is up over 5% on September 29, 2026, following a major announcement that pharmaceutical giant AstraZeneca is making a $2.0 billion strategic equity investment in the company. ### 💡 Key Deal Highlights - Direct Equity Purchase: AstraZeneca is buying roughly 109,000 convertible preferred shares at an effective price of $18.36 per common share, representing a significant premium. - Ownership Stake: The transaction gives AstraZeneca a ~12% stake in Summit's outstanding common stock. - No Territory/License Sale: Summit retains full economic control and rights to its flagship bispecific antibody, ivonescimab , in its designated territories. ### 🔬 Clinical Collaboration - Combination Trials: The two drugmakers agreed to evaluate Summit’s *ivonescimab* alongside AstraZeneca’s experimental cancer therapy, *sonesitatug vedotin* , targeting gastrointestinal cancers. - Expanded Scope: A signed memorandum of understanding paves the way to test ivonescimab with additional AstraZeneca antibody-drug conjugates (ADCs). ### 🗓 Upcoming Catalysts - Deal Closure: The transaction is slated to wrap up by the end of the week. - FDA Decision: Investors are also eyeing a lo
Frequently asked questions
Why did Summit Therapeutics Inc. (SMMT) stock fall on Sep 29, 2026?
Summit Therapeutics fell 13.4% on September 29, 2026, closing at $16.35. A Form 8-K filing was submitted on that date, though the specific disclosure triggering the decline is not detailed in available sources. Stifel reiterated a Buy rating with a $38 price target, suggesting analyst confidence despite the session's weakness.
How much did SMMT stock fall on Sep 29, 2026?
SMMT fell 13.4% during the Sep 29, 2026 trading session.
What were the main drivers behind SMMT's move?
Form 8-K filing; Analyst support amid weakness.